DZ3154A1 - 1-Amino triazolo(4,3-A)quinazoline-5-ones et/ou-5-thiones inhibitrices de phosphodiestérases IV. - Google Patents

1-Amino triazolo(4,3-A)quinazoline-5-ones et/ou-5-thiones inhibitrices de phosphodiestérases IV.

Info

Publication number
DZ3154A1
DZ3154A1 DZ003154A DZ003154A DZ3154A1 DZ 3154 A1 DZ3154 A1 DZ 3154A1 DZ 003154 A DZ003154 A DZ 003154A DZ 003154 A DZ003154 A DZ 003154A DZ 3154 A1 DZ3154 A1 DZ 3154A1
Authority
DZ
Algeria
Prior art keywords
thiones
phosphodiesterases
quinazoline
inhibitors
ones
Prior art date
Application number
DZ003154A
Other languages
English (en)
French (fr)
Inventor
Bernard Gaudilliere
Remi Lavalette
Charles Andrianjara
Francine Breuzard
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3154A1 publication Critical patent/DZ3154A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DZ003154A 1999-04-28 2000-04-28 1-Amino triazolo(4,3-A)quinazoline-5-ones et/ou-5-thiones inhibitrices de phosphodiestérases IV. DZ3154A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905398A FR2792938B1 (fr) 1999-04-28 1999-04-28 NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
PCT/FR2000/001174 WO2000066584A1 (fr) 1999-04-28 2000-04-28 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES ET/OU -5-THIONES INHIBITRICES DE PHOSPHODIESTERASES IV

Publications (1)

Publication Number Publication Date
DZ3154A1 true DZ3154A1 (fr) 2000-11-09

Family

ID=9544983

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003154A DZ3154A1 (fr) 1999-04-28 2000-04-28 1-Amino triazolo(4,3-A)quinazoline-5-ones et/ou-5-thiones inhibitrices de phosphodiestérases IV.

Country Status (34)

Country Link
US (1) US6828315B1 (pt)
EP (1) EP1177195B1 (pt)
JP (1) JP2002543199A (pt)
KR (1) KR20020008166A (pt)
CN (1) CN1352644A (pt)
AP (1) AP2001002309A0 (pt)
AT (1) ATE234840T1 (pt)
AU (1) AU4411500A (pt)
BG (1) BG106026A (pt)
BR (1) BR0010072A (pt)
CA (1) CA2388658A1 (pt)
DE (1) DE60001735T2 (pt)
DK (1) DK1177195T3 (pt)
DZ (1) DZ3154A1 (pt)
EA (1) EA004373B1 (pt)
EE (1) EE200100566A (pt)
ES (1) ES2194779T3 (pt)
FR (1) FR2792938B1 (pt)
HK (1) HK1044938B (pt)
HR (1) HRP20010794B1 (pt)
HU (1) HUP0202656A3 (pt)
IL (1) IL146178A0 (pt)
IS (1) IS6114A (pt)
MA (1) MA27343A1 (pt)
MX (1) MXPA01010888A (pt)
NO (1) NO20015235L (pt)
OA (1) OA11875A (pt)
PL (1) PL351951A1 (pt)
PT (1) PT1177195E (pt)
SK (1) SK15322001A3 (pt)
TR (1) TR200103099T2 (pt)
WO (1) WO2000066584A1 (pt)
YU (1) YU76401A (pt)
ZA (1) ZA200108847B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
MXPA03010679A (es) * 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
EP1285922A1 (en) * 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
US7608716B2 (en) 2002-11-06 2009-10-27 Aska Pharmaceutical Co., Ltd. Pyrazolonaphthyridine derivative
JP4671104B2 (ja) 2003-01-09 2011-04-13 アステラス製薬株式会社 ピロロピリダジン誘導体
CN1972684A (zh) * 2004-04-23 2007-05-30 细胞基因公司 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103224498B (zh) * 2013-05-07 2015-10-28 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865824A (en) * 1972-03-07 1975-02-11 Icn Pharmaceuticals 2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines
US3850932A (en) * 1973-06-28 1974-11-26 Sandoz Ag 5-(2-carboxy and 2-carboalkoxy-phenylamino)-1,2,4-triazolo-quinazolines
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
ATE214700T1 (de) * 1995-06-06 2002-04-15 Pfizer Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4 3-alpha)pyridine
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.

Also Published As

Publication number Publication date
FR2792938B1 (fr) 2001-07-06
PL351951A1 (en) 2003-07-14
DE60001735D1 (de) 2003-04-24
US6828315B1 (en) 2004-12-07
JP2002543199A (ja) 2002-12-17
HRP20010794A2 (en) 2003-04-30
HK1044938A1 (en) 2002-11-08
EE200100566A (et) 2003-02-17
CA2388658A1 (en) 2000-11-09
EA200100994A1 (ru) 2002-06-27
NO20015235D0 (no) 2001-10-26
DE60001735T2 (de) 2004-02-05
WO2000066584A1 (fr) 2000-11-09
MXPA01010888A (es) 2003-06-24
HUP0202656A3 (en) 2004-12-28
BG106026A (bg) 2002-05-31
WO2000066584B1 (fr) 2001-02-15
EP1177195B1 (fr) 2003-03-19
SK15322001A3 (sk) 2002-11-06
HK1044938B (zh) 2003-12-24
HUP0202656A2 (hu) 2002-12-28
AP2001002309A0 (en) 2001-12-31
TR200103099T2 (tr) 2002-12-23
CN1352644A (zh) 2002-06-05
PT1177195E (pt) 2003-07-31
KR20020008166A (ko) 2002-01-29
ZA200108847B (en) 2002-11-27
IL146178A0 (en) 2002-07-25
FR2792938A1 (fr) 2000-11-03
HRP20010794B1 (en) 2004-06-30
EA004373B1 (ru) 2004-04-29
DK1177195T3 (da) 2003-07-14
EP1177195A1 (fr) 2002-02-06
IS6114A (is) 2001-10-19
AU4411500A (en) 2000-11-17
YU76401A (sh) 2004-07-15
ATE234840T1 (de) 2003-04-15
ES2194779T3 (es) 2003-12-01
MA27343A1 (fr) 2005-06-01
BR0010072A (pt) 2002-02-05
NO20015235L (no) 2001-12-21
OA11875A (en) 2006-03-29

Similar Documents

Publication Publication Date Title
DZ3154A1 (fr) 1-Amino triazolo(4,3-A)quinazoline-5-ones et/ou-5-thiones inhibitrices de phosphodiestérases IV.
ATE251161T1 (de) Triazolo(4,5-d)pyrimidin-derivate als antithrombotische mittel
ATE251623T1 (de) Imidazo(1,2-a)pyridin- und pyrazolo(2,3- a)pyridinderivate
ZA200104118B (en) Substituted benzimidazoles and their use as PARP inhibitors.
ZA200108291B (en) Diaminothiazoles and their use for inhibiting protein kinases.
NO20021356D0 (no) Alkylendiamin-substituerte pyrazolo[1,5,-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner
ZA991946B (en) Pyrazolopyrimidines and pyrazolotriazines.
MA26771A1 (fr) Benzoheterocycles et leur utilisation comme inhibiteurs de mek.
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
HK1027624A1 (en) Solid-state fluorometer and methods of use therefor.
NO20015062L (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
NL1007839A1 (nl) Formulering en gebruik.
EE04494B1 (et) 1-oksa-, asa- ja tianaftaleen-2-oon biseetrid fosfolambaani inhibiitoritena
IT1307149B1 (it) Complesso di gruppo motopropulsore e ruota.
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
SI1177195T1 (en) 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV
PT1325010E (pt) 3, 4-di-hidropirimido [1,2-a] pirimidinas e 3, 4-di-hidropirazino [1,2-a] pirimidinas substituidas
AU6976400A (en) 1,2,3-thiadiazoles and their use as cox-2 inhibitors
ES1037378Y (es) Pasarela enrollable.
ZA200108250B (en) Formulation arrays and use thereof.
ES1033671Y (es) Monedero antivandalico antivuelco.
SI1325010T1 (en) Substituted 3.4-dihydro-pyrimido (1,2-a)pyrimidines and 3.4-dihydropyrazino (1,2-a)pyrimidines
ITFI990168A0 (it) Impianto e kit per la fabbricazione di accoppiati tessili.
AU2002214441A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain